Volume 6 Issue 1
Jan.  2015
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2015.01.011
  • Received Date: 2014-02-08
  • Publish Date: 2015-01-30
  • loading
  • [1] Bartalena L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy[J]. J Clin Endocrinol Metab, 2011, 96:592-599. doi:  10.1210/jc.2010-2329
    [2] Briceño CA, Gupta S, Douglas RS. Advances in the management of thyroid eye disease[J].Int Ophthalmol Clin, 2013, 53:93-101.
    [3] Stan MN, Bahn RS. Risk factors for development or deterioration of Graves' ophthalmopathy[J]. Thyroid, 2010, 20:777-783. doi:  10.1089/thy.2010.1634
    [4] Dolman PJ. Evaluating Graves' orbitopathy[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26:229-248. doi:  10.1016/j.beem.2011.11.007
    [5] Khalilzadeh O, Noshad S, Rashidi A, et al. Graves' ophthalmopathy:a review of immunogenetics[J]. Curr Genomics, 2011, 12:564-575. doi:  10.2174/138920211798120844
    [6] Bednarczuk T, Gopinath B, Ploski R, et al. Susceptibility genes in Graves' ophthalmopathy:searching for a needle in a haystack?[J]. Clin Endocrinol, 2007, 67:3-19. doi:  10.1111/j.1365-2265.2007.02854.x
    [7] Wiersinga WM. Autoimmunity in Graves' ophthalmopathy:the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?[J]. J Clin Endocrinol Metab, 2011, 96:2386-2394. doi:  10.1210/jc.2011-0307
    [8] Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy:the role of the TSh receptor[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26:281-289. doi:  10.1016/j.beem.2011.10.003
    [9] Bahn RS. Graves' ophthalmopathy[J]. N Engl J Med, 2010, 362:726-738. doi:  10.1056/NEJMra0905750
    [10] Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J]. Immunol Rev, 2008, 224:166-182. doi:  10.1111/j.1600-065X.2008.00662.x
    [11] Jacobson EM, Tomer Y. The genetic basis of thyroid autoimmunity[J]. Thyroid, 2007, 17:949-961. doi:  10.1089/thy.2007.0153
    [12] Yin X, Latif R, Bahn R, et al. Genetic profiling in Graves' disease:further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy[J]. Thyroid, 2012, 22:730-736. doi:  10.1089/thy.2012.0007
    [13] Allahabadia A, Heward JM, Nithiyananthan R, et al. MHC class Ⅱ region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease[J]. Lancet, 2001, 358:984-985. doi:  10.1016/S0140-6736(01)06125-6
    [14] Chistyakov DA, Savost'anov KV, Turakulov RI, et al.Genetic determinants of Graves disease[J]. Mol Genet Metab, 2000, 71:66-69. doi:  10.1006/mgme.2000.3042
    [15] Kula D, Bednarczuk T, Jurecka-Lubieniecka B, et al. Interaction of HLA-DRB1 alleles with CTLA-4 in the predisposition to Graves' disease:the impact of DRB1*07[J]. Thyroid, 2006, 16:447-453. doi:  10.1089/thy.2006.16.447
    [16] Jacobson EM, Huber A, Tomer Y. The HLA gene complex in thyroid autoimmunity:from epidemiology to etiology[J].J Autoimmun, 2008, 30:58-62. doi:  10.1016/j.jaut.2007.11.010
    [17] Du L, Yang J, Huang J. The associations between the polymorphisms in the CTLA-4 gene and the risk of Graves' disease in the Chinese population[J]. BMC Med Genet, 2013, 14:46. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=2420f457b9135346ec2fe695bdabe86f
    [18] 沈飞霞, 汪大望, 权金星. TAO CTLA-4基因外显子1 A/G多态性相关性研究[J].温州医学院院报, 2005, 35:356-358.
    [19] 陈光明, 沈飞霞. Graves眼病与CTLA-4基因第1外显子A49G多态性及临床特点的相关性研究[J].实用医学杂志, 2007, 23:642-644. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=syyxzz200705014
    [20] Yin X, Latif R, Bahn R, et al. Genetic profiling in Graves' disease:further evidence for lack of a distinct genetic contribution to Graves' ophthalmopathy[J]. Thyroid, 2012, 22:730-736. doi:  10.1089/thy.2012.0007
    [21] Gianoukakis AG, Khadavi N, Smith TJ. Cytokines, Graves' disease, and thyroid-associated ophthalmopathy[J]. Thyroid, 2008, 18:953-958. doi:  10.1089/thy.2007.0405
    [22] Kamizono S, Hiromatsu Y, Seki N, et al. A polymorphism of the 5' flanking region of tumour necrosis factor alpha gene is associated with thyroid-associated oph-thalmopathy in Japanese[J]. Clin Endocrinol, 2000, 52:759-764. doi:  10.1046/j.1365-2265.2000.01011.x
    [23] 阎胜利, 王迎雪.甲状腺相关眼病与肿瘤坏死因子α基因启动子区-863C/A多态性相关性的初步研究[J].中华眼科杂志, 2005, 41:786-790. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyk200509005
    [24] Bednarczuk T, Hiromatsu Y, Seki N, et al. Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy[J]. Hum Immunol, 2004, 65:632-639. doi:  10.1016/j.humimm.2004.02.033
    [25] Anvari M, Khalilzadeh O, Esteghamati A, et al.Genetic susceptibility to Graves' ophthalmopathy:the role of polymorphisms in proinflammatory cytokine genes[J]. Eye, 2010, 24:1058-1063. doi:  10.1038/eye.2009.244
    [26] Ploski R, Szymański K, Bednarczuk T. The genetic basis of Graves' disease[J]. Curr Genomics, 2011, 12:542-563. doi:  10.2174/138920211798120772
    [27] Brand OJ, Gough SC. Immunogenetic mechanisms leading to thyroid autoimmunity:recent advances in identifying susceptibility genes and regions[J]. Curr Genomics, 2011, 12:526-541.) doi:  10.2174/138920211798120790
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (160) PDF downloads(4) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return